var data={"title":"Calcitriol (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcitriol (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/770723?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcitriol-systemic-drug-information\" class=\"drug drug_general\">see &quot;Calcitriol (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=calcitriol-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcitriol (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561742\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rocaltrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561743\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Calcijex;</li>\n      <li>Calcitriol Injection;</li>\n      <li>Calcitriol-Odan;</li>\n      <li>Rocaltrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204369\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vitamin D Analog</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204393\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypocalcemia secondary to hypoparathyroidism:</b> Oral: 1 mcg once daily for the first 5 days of life </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate regimen: Oral: 0.02 to 0.06 mcg/kg/day; similar dosage has also been described in neonates with DiGeorge syndrome (Miller 1983) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypocalcemic tetany: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.05 mcg/kg once daily for 5 to 12 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 0.25 mcg/dose once daily, followed by 0.01 to 0.10 mcg/kg/day divided in 2 doses (maximum daily dose: 2 mcg) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204372\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=calcitriol-systemic-drug-information\" class=\"drug drug_general\">see &quot;Calcitriol (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypocalcemia in patients with chronic kidney disease (CKD)/Metabolic bone disease:</b> Limited data available: Indicated when serum levels of 25(OH)D are &gt;30 ng/mL (75 nmol/L) and serum levels of intact parathyroid hormone (iPTH) are above the target range for the stage of CKD; serum levels of corrected total calcium are &lt;9.5 to 10 mg/dL (2.37 mmol/L) and serum levels of phosphorus in children are less than age-appropriate upper limits of normal (K/DOQI Guidelines 2005): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CKD Stages 2 to 4: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;10 kg: 0.05 mcg every other day </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10 to 20 kg: 0.1 to 0.15 mcg daily </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;20 kg: 0.25 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Dosage adjustment: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If iPTH decrease is &lt;30% after 3 months of therapy and serum levels of calcium and phosphorus are within the target ranges based upon the CKD Stage, increase dosage by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If iPTH decrease &lt; target range for CKD stage hold calcitriol therapy until iPTH increases to above target range; resume therapy at half the previous dosage (if dosage &lt;0.25 mcg capsule or 0.05 mcg liquid, use every other day therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If serum levels of total corrected calcium exceed 10.2 mg/dL (2.37 mmol/L) hold calcitriol therapy until serum calcium decreased to &lt;9.8 mg/dL (2.37 mmol/L); resume therapy at half the previous dosage (if dosage &lt;0.25 mcg capsule or 0.05 mcg liquid, use every other day therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If serum levels of phosphorus increase to &gt; age-appropriate upper limits, hold calcitriol therapy (initiate or increase phosphate binders until the levels of serum phosphorus decrease to age-appropriate limits); resume therapy at half the previous dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CKD Stage 5 on dialysis: Oral, IV: Serum calcium times phosphorus product (Ca x P) should not exceed 65 mg<sup>2</sup>/dL<sup>2</sup> for infants and children &lt;12 years of age and 55 mg<sup>2</sup>/dL<sup>2</sup> for adolescents, serum phosphorus should be within target, serum calcium &lt;10 mg/dL (2.37 mmol/L) or &lt;10.5 mg/dL (2.5 mmol/L) if iPTH &gt;1,000 pg/mL: <b>Note:</b> If undergoing hemodialysis, doses should be given on dialysis days.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">iPTH 300 to 500 pg/mL: 0.0075 mcg/kg 3 times weekly; maximum dose: 0.25 mcg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">iPTH &gt;500 to 1,000 pg/mL: 0.015 mcg/kg 3 times weekly; maximum dose: 0.5 mcg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">iPTH &gt;1,000 pg/mL: 0.025 mcg/kg 3 times weekly; maximum dose: 1 mcg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Dosage adjustment: If iPTH decrease is &lt;30% after 3 months of therapy and serum levels of calcium and phosphorus are within the target ranges based upon the CKD Stage 5, increase dosage by 50% </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note: Intermittent administration of calcitriol by IV or oral routes is more effective than daily oral calcitriol in lowering iPTH levels</b> (KDIGO 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypoparathyroidism/pseudohypoparathyroidism:</b> Oral (evaluate dosage at 2- to 4-week intervals): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Limited data available: 0.02 to 0.06 mcg/kg once daily (Sperling 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 5 years: Oral: 0.25 to 0.75 mcg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents: Oral: 0.5 to 2 mcg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Secondary hyperparathyroidism associated with moderate to severe CKD in patients not yet on dialysis (predialysis): Note:</b> KDIGO recommends against routine vitamin D supplement or analog use to suppress PTH concentrations in the absence of suspected or documented deficiency (KDIGO 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;3 years: Oral: 0.01 to 0.015 mcg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years and Adolescents: Oral: 0.25 mcg once daily; may increase if necessary to 0.5 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D-dependent rickets:</b> Infants, Children, and Adolescents: Oral: Initial: 0.25 to 2 mcg once daily; adjust dose base on clinical response, use lower dose once rickets has healed (Kliegman 2016) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypocalcemia in patients on chronic renal dialysis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Initial: 0.25 mcg daily; may increase dose by 0.25 mcg daily at 4- to 8-week intervals, up to 0.5 to 1 mcg daily; patients with normal or mildly decreased serum calcium levels may respond to 0.25 mcg every other day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 1 to 2 mcg 3 times weekly approximately every other day. Adjust dose by 0.5 to 1 mcg at 2- to 4-week intervals; dosing range: 0.5 to 4 mcg 3 times weekly. Gradual dose reduction and discontinuation of therapy may be necessary as PTH levels decrease below target of (1.5 to 3 x ULN) in response to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypocalcemia in hypoparathyroidism/pseudohypoparathyroidism:</b> Oral: Initial: 0.25 mcg daily (may adjust dose at 2- to 4-week intervals); range: 0.5 to 2 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Secondary hyperparathyroidism associated with moderate to severe CKD in patients not yet on dialysis:</b> Oral: 0.25 mcg daily; may increase to 0.5 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> KDIGO guidelines do not recommend routine vitamin D therapy (with vitamin D supplements or a vitamin D analog [eg, calcitriol]) for progressive or persistently elevated PTH concentrations in CKD patients (stages 3 to 5) not on dialysis in the absence of suspected/documented Vitamin D deficiency. Caution is advised to avoid hypercalcemia or elevated phosphate levels (KDIGO 2009; KDIGO 2012; Uhlig 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561814\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rocaltrol: 0.25 mcg, 0.5 mcg [contains fd&amp;c yellow #6 (sunset yellow), methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mcg, 0.5 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rocaltrol: 1 mcg/mL (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mcg/mL (15 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561746\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204373\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered with or without meals; when administering small doses from the liquid-filled capsules, consider the following concentration for Rocaltrol: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.25 mcg capsule = 0.25 mcg per 0.17 mL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.5 mcg capsule = 0.5 mcg per 0.17 mL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: May be administered undiluted as a bolus dose IV through the catheter at the end of hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561777\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Oral capsule, injection, solution: Store at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204370\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Management of hypocalcemia and resultant metabolic bone disease in patients on chronic renal dialysis (FDA approved in ages &ge;18 years) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure not yet on dialysis (FDA approved in ages &ge;3 years and adults); management of hypocalcemia in patients with hypoparathyroidism (FDA approved in ages &ge;1 year and adults) and pseudohypoparathyroidism (FDA approved in ages &ge;6 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561739\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calcitriol may be confused with alfacalcidol, calcifediol, Calciferol, calcitonin, calcium carbonate, captopril, colestipol, paricalcitol, ropinirole</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dosage is expressed in mcg (micrograms), <b>not</b> mg (milligrams); rare cases of acute overdose have been reported</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561767\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Apathy, drowsiness, headache, hyperthermia, metallic taste, psychosis, sensory disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, erythema multiforme, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Albuminuria, calcinosis, decreased libido, dehydration, growth suppression, hypercalcemia, hypercholesterolemia, polydipsia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, nausea, pancreatitis, stomach pain, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hypercalciuria, nocturia, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site (mild)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Dystrophy, myalgia, ostealgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis, photophobia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Calcium nephrolithiasis, increased blood urea nitrogen, increased serum creatinine, polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agitation, anaphylaxis, apprehension, hypermagnesemia, hyperphosphatemia, hypervitaminosis D, increased hematocrit, increased hemoglobin, increased neutrophils, increased serum alkaline phosphatase, insomnia, limb pain, lymphocytosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561762\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Oral, injection: Hypersensitivity to calcitriol or any component of the formulation; hypercalcemia, vitamin D toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Oral, injection: Hypersensitivity to calcitriol, vitamin D or its analogues or derivatives, or any component of the formulation or container; hypercalcemia, vitamin D toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561763\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease. Withhold pharmacologic doses of vitamin D and its derivatives during therapy to avoid the potential for hypercalcemia to develop. In addition, several months may be required for ergocalciferol levels to return to baseline in patients switching from ergocalciferol therapy to calcitriol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypercalcemia: Monitor calcium levels closely with initiation of therapy and with dose adjustments; discontinue use promptly in patients who develop hypercalcemia. Avoid abrupt dietary modifications (eg, increased intake of dairy products) which may lead to hypercalcemia; adjust calcium intake if indicated and maintain adequate hydration. Chronic hypercalcemia can result in generalized vascular and soft tissue calcification. Immobilized patients may be at a higher risk for hypercalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Malabsorption syndrome: Use oral calcitriol with caution in patients with malabsorption syndromes; efficacy may be limited and/or response may be unpredictable. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use of calcitriol for the treatment of secondary hyperparathyroidism associated with CKD is not recommended in patients with rapidly worsening kidney function or in noncompliant patients. Increased serum phosphate levels in patients with renal failure may lead to ectopic calcification; the use of an aluminum-containing phosphate binder is recommended along with a low phosphate diet in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Calcium: Adequate dietary (supplemental) calcium is necessary for clinical response to vitamin D. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac glycosides: Use with caution in patients taking cardiac glycosides; digitalis toxicity is potentiated by hypercalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Magnesium-containing products: Concomitant use with magnesium-containing products such as antacids may lead to hypermagnesemia in patients receiving chronic renal dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Coconut oil: Products may contain coconut oil (capsule).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Palm seed oil: Products may contain palm seed oil (oral solution).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine: Some products may contain tartrazine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Calcium-phosphate product: Discontinue use immediately in adult patients with a calcium-phosphate product  (serum calcium times phosphorus) &gt;70 mg<sup>2</sup>/dL<sup>2</sup>; may resume therapy at decreased doses when levels are appropriate. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204383\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor serum calcium levels closely; the calcitriol dosage should be adjusted accordingly; serum calcium times phosphorus product (Ca x P) should not exceed 65 mg<sup>2</sup>/dL<sup>2</sup> for infants and children &lt;12 years of age and 55 mg<sup>2</sup>/dL<sup>2</sup> for adolescents (KDOQI 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561772\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561769\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=107355&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May diminish the therapeutic effect of Calcitriol (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Calcitriol (Systemic) may increase the serum concentration of Magnesium Salts.  Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of Calcitriol (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561757\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561758\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in some animal reproduction studies. Maternal calcitriol may be detected in the fetal circulation. Mild hypercalcemia has been reported in a newborn following maternal use of calcitriol during pregnancy. Adverse effects on fetal development were not observed with use of calcitriol during pregnancy in women (N=9) with pseudovitamin D-dependent rickets. Doses were adjusted every 4 weeks to keep calcium concentrations within normal limits (Edouard 2011). If calcitriol is used for the management of hypoparathyroidism in pregnancy, dose adjustments may be needed as pregnancy progresses and again following delivery. Vitamin D and calcium levels should be monitored closely and kept in the lower normal range (Callies 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204374\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Manufacturer's labeling:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis patients: Serum calcium (at least twice weekly during titration, followed by monthly once on optimal dose), phosphorus, magnesium, and alkaline phosphate monitored periodically</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypoparathyroid patients: Serum calcium (check at least twice weekly during dose titration, followed by periodically), phosphorus, 24-hour urinary calcium monitored periodically</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Predialysis patients: Serum calcium (check at least twice weekly during dose titration), phosphorus, alkaline phosphatase, creatinine, and intact PTH, initially; then serum calcium, phosphorus, alkaline phosphatase, and creatinine monthly x 6 months, then periodically. Intact PTH should be monitored every 3 to 4 months. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV therapy: Serum calcium and phosphorus twice weekly (following initiation and during dosage adjustments) and periodically during therapy; magnesium, alkaline phosphatase, and 24 hour urinary calcium and phosphorous periodically</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>KDIGO guidelines (2009) and KDOQI Commentary (Uhlig 2010):  </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Frequency of monitoring should be based on the presence and magnitude of abnormalities, as well as the rate of CKD progression. Reasonable intervals are:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 2 to 3: Serum calcium and phosphorus, every 6 to 12 months; PTH: Monitor based on baseline level and CKD progression; alkaline phosphatase once; 25 hydroxyvitamin D once then based on level and treatments. <b>Note:</b> Adults may not need monitoring until CKD stage 3.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 4: Serum calcium and phosphorus every 3 to 6 months; PTH every 6 to 12 months; alkaline phosphatase every 12 months or more frequently in the presence of increased PTH, 25 hydroxyvitamin D once yearly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 5 (includes 5D): Serum calcium and phosphorus every 1 to 3 months; PTH every 3 to 6 months; alkaline phosphatase every 12 months or more frequently in the presence of increased PTH, 25 hydroxyvitamin D once then based on level and treatments.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204375\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total serum calcium: Children, Adolescents, and Adults: CKD stages 2 to 5D: Maintain normal ranges; preferably on the lower end for stage 5 (KDIGO 2009; KDOQI 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus (KDIGO 2009): Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stages 2 to 5: Maintain normal ranges</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 5D: Lower elevated phosphorus levels toward the normal range</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561780\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Calcitriol, the active form of vitamin D (1,25 hydroxyvitamin D<sub>3</sub>), binds to and activates the vitamin D receptor in kidney, parathyroid gland, intestine, and bone, stimulating intestinal calcium transport and absorption. It reduces PTH levels and improves calcium and phosphate homeostasis by stimulating bone resorption of calcium and increasing renal tubular reabsorption of calcium. Decreased renal conversion of vitamin D to its primary active metabolite (1,25 hydroxyvitamin D) in chronic renal failure leads to reduced activation of vitamin D receptor, which subsequently removes inhibitory suppression of parathyroid hormone (PTH) release; increased serum PTH (secondary hyperparathyroidism) reduces calcium excretion and enhances bone resorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561783\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: 2 hours; maximum effect: 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral, IV: 3 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 99.9% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily to calcitroic acid and a lactone metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children 1.8-16 years undergoing peritoneal dialysis: 27.4 hours; Healthy adults: 5 to 8 hours; Hemodialysis: 16 to 22 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 3 to 6 hours; Hemodialysis: 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (27%); urine (7%, unchanged in 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Children 1.8 to 16 years undergoing peritoneal dialysis: 15.3 mL/hour/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204419\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Chronic kidney disease (CKD) (KDIGO 2013; KDOQI 2002): Children &ge;2 years, Adolescents, and Adults: GFR &lt;60 mL/minute/1.73 m<sup>2</sup> or kidney damage for &gt;3 months; stages of CKD are described below: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CKD stage 1: Kidney damage with normal or increased GFR; GFR &gt;90 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CKD stage 2: Kidney damage with mild decrease in GFR; GFR 60 to 89 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CKD stage 3: Moderate decrease in GFR; GFR 30 to 59 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CKD stage 4: Severe decrease in GFR; GFR 15 to 29 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CKD stage 5: Kidney failure; GFR &lt;15 mL/minute/1.73 m<sup>2</sup> or dialysis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561819\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Calcitriol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mcg (100): $120.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mcg (100): $193.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Rocaltrol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mcg (30): $56.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mcg (100): $294.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcitriol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg/mL (1 mL): $9.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcitriol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg/mL (15 mL): $179.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rocaltrol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg/mL (15 mL): $235.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46329904\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Altrol (MX);</li>\n      <li>Bonkey (PK);</li>\n      <li>Cacare (TH);</li>\n      <li>Calciget (IN);</li>\n      <li>Calcijex (AE, BR, CN, HU, KW, MY, PH, PK, QA, SA, SG);</li>\n      <li>Calciraquiferol (AR);</li>\n      <li>Calcit (ID);</li>\n      <li>Calcit SG (LK, TH);</li>\n      <li>Caleobrol (CL, PY);</li>\n      <li>Caltril (BD);</li>\n      <li>Decostriol (DE, TH);</li>\n      <li>Dexiven (AR);</li>\n      <li>Dicaltrol (BD);</li>\n      <li>Improcal (BD);</li>\n      <li>Kolkatriol (ID);</li>\n      <li>Kosteo (AU);</li>\n      <li>Meditrol (LK, TH, VN);</li>\n      <li>Nafartol (MX);</li>\n      <li>Osteo D (BG, TH);</li>\n      <li>Osteocap (MY);</li>\n      <li>Osteodiol (HK);</li>\n      <li>Osteofem (ID);</li>\n      <li>Osteotriol (DE);</li>\n      <li>Ostriol (BD, BR);</li>\n      <li>Renatriol (CH, DE);</li>\n      <li>Renatrol (PH);</li>\n      <li>Rocaltrol (AE, AU, BB, BE, BG, BH, BR, CH, CL, CO, CU, CZ, DE, EC, EE, ES, FR, GB, HK, HR, HU, ID, IN, IT, JO, JP, LK, LU, LV, MT, MY, NL, NO, NZ, PE, PH, PK, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, UY, VE, VN);</li>\n      <li>Roical (SG);</li>\n      <li>Rolsical (IN);</li>\n      <li>Sical (AU);</li>\n      <li>Sigmatriol (UY);</li>\n      <li>Sitriol (AU);</li>\n      <li>Tirocal (MX);</li>\n      <li>Vitadia (UY);</li>\n      <li>Vitadol (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calcijex injection solution (calcitriol systemic) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calcitriol capsules [prescribing information]. Sellersville, PA: Teva Pharmaceuticals; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Callies F, Arlt W, Scholz HJ, Reincke M, Allolio B. Management of hypoparathyroidism during pregnancy--report of twelve cases. <i>Eur J Endocrinol</i>. 1998;139(3):284-289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-pediatric-drug-information/abstract-text/9758437 /pubmed\" target=\"_blank\" id=\"9758437 \">9758437 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edouard T, Alos N, Chabot G, et al, &ldquo;Short- and Long-Term Outcome of Patients with Pseudo-Vitamin D Deficiency Rickets Treated with Calcitriol,&rdquo; <i>J Clin Endocrinol Metab</i>, 2011, 96(1):82-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-pediatric-drug-information/abstract-text/20926527/pubmed\" target=\"_blank\" id=\"20926527\">20926527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2005;46(4 Suppl 1):S1-121. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 1. Evaluation of calcium and phosphorus metabolism. <i>Am J Kidney Dis</i>. 2003;42(4 Suppl 3):52-57. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 3. Evaluation of serum phosphorus levels. <i>Am J Kidney Dis</i>. 2003;42(4 Suppl 3):62-63. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, part 4. Definition and classification of stages of chronic kidney disease. <i>Am J Kidney Dis</i>. 2002;39(2 Suppl 1):46-75. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, &quot;KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),&quot; <i>Kidney Int Suppl</i>, 2009, 76(S113):1-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-pediatric-drug-information/abstract-text/19644521/pubmed\" target=\"_blank\" id=\"19644521\">19644521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, &quot;KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease,&quot;<i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson's Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller JD, Bowker BM, Cole DE, Guyda HJ. DiGeorge's syndrome in monozygotic twins. Treatment with calcitriol. <i>Am J Dis Child</i>. 1983;137(5):438-440.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-pediatric-drug-information/abstract-text/6687780 /pubmed\" target=\"_blank\" id=\"6687780 \">6687780 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocaltrol capsule (calcitriol) [prescribing information]. Parsippany NJ: Validus Pharmaceuticals LLC; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchez CP. Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. <i>Paediatr Drugs</i>. 2003;5(11):763-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-pediatric-drug-information/abstract-text/14580225 /pubmed\" target=\"_blank\" id=\"14580225 \">14580225 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uhlig K, Berns JS, Kestenbaum B, et al, &ldquo;KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD), <i>Am J of Kidney Disease</i>, 2010, 55 (5):773-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-pediatric-drug-information/abstract-text/20363541/pubmed\" target=\"_blank\" id=\"20363541\">20363541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zi&oacute;lkowska H. Minimizing bone abnormalities in children with renal failure. <i>Paediatr Drugs</i>. 2006;8(4):205-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-pediatric-drug-information/abstract-text/16898852 /pubmed\" target=\"_blank\" id=\"16898852 \">16898852 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 107355 Version 43.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28561742\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28561743\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F46204369\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F46204393\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F46204372\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28561814\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F28561746\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46204373\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F28561777\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46204370\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28561739\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28561767\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28561762\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28561763\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46204383\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28561772\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28561769\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28561757\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28561758\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46204374\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F46204375\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28561780\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F28561783\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F46204419\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28561819\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46329904\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/107355|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcitriol-systemic-drug-information\" class=\"drug drug_general\">Calcitriol (systemic): Drug information</a></li><li><a href=\"topic.htm?path=calcitriol-systemic-patient-drug-information\" class=\"drug drug_patient\">Calcitriol (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}